Highlights

• Cipla reports FY26 revenue of Rs 28,163 crore despite margin pressure during the fiscal year.
• North America business crosses US$ 400 million revenue benchmark during FY26 financial year.
• Cipla shares rise 5.33% on NSE following quarterly earnings and operational business updates.

Cipla Limited (NSE:CIPLA) reported its Q4 FY26 and FY26 financial performance on May 13, 2026, highlighting revenue growth across multiple business segments despite lower EBITDA and profit margins compared to the previous year. The company reported annual revenue of Rs 28,163 crore, compared to Rs 27,548 crore in FY25.

Quarterly Financial Performance

For Q4 FY26, Cipla reported consolidated revenue from operations of Rs 6,541 crore against Rs 6,730 crore in Q4 FY25. EBITDA stood at Rs 997 crore with EBITDA margin at 15.2%, compared to Rs 1,538 crore and 22.8% margin in the corresponding quarter last year.

Profit after tax attributable to shareholders came at Rs 555 crore versus Rs 1,222 crore in Q4 FY25. PAT margin stood at 8.5% during the quarter. Research and development expenditure for the quarter was Rs 509 crore, representing 7.8% of revenue.

FY26 Business Performance

For FY26, EBITDA was reported at Rs 5,925 crore compared to Rs 7,128 crore in FY25, while PAT stood at Rs 3,879 crore against Rs 5,273 crore in the previous fiscal year. EBITDA margin for FY26 came at 21.0%, while PAT margin was 13.8%.

The One India business contributed 45% to total FY26 revenue, while North America accounted for 24%. One Africa contributed 15%, and Emerging Markets and Europe represented 13% of the consolidated revenue mix.

Source: Company Filing

India and Product Portfolio Updates

The company stated that it maintained its second rank in the chronic segment in India with chronic mix improving to 60.2%. Cipla launched products including Voltido Trio Ciphaler, Huena, Zemdri and Empacip during the year.

The trade generics business reported growth across categories with 17 new launches in FY26. Consumer health brands including Nicotex, Omnigel and Cipladine maintained market positions during the fiscal year.

North America and Africa Operations

North America business crossed the US$ 400 million benchmark during FY26. The company received approval for the first AB-rated gVentolin with CGT. Cipla stated that launch is expected in the coming months.

Africa operations reported continued growth, with South Africa private market business growing at 1.4 times the market growth rate. The company also reported 18 launches across African markets during FY26.

Balance Sheet and Cash Position

Cash and cash equivalents stood at Rs 11,140 crore as of March 2026, compared to Rs 10,807 crore in March 2025. Total debt remained limited with borrowings at Rs 258 crore and lease liabilities at Rs 356 crore.

The company stated that it maintained a net cash position exceeding US$ 1 billion during FY26.

Share Performance

Cipla shares on the NSE traded at Rs 1,391.80, rising 4.84% on May 14, 2026. The stock opened at Rs 1,362.20 and touched an intraday high of Rs 1,432.10. The previous close stood at Rs 1,327.60, while VWAP for the session was Rs 1,413.42.

Source: Trading View

Key Risks

• Margin pressure may continue due to higher operating and employee-related expenditure.
  • Regulatory approvals and product launches remain subject to global compliance requirements.
  • Currency fluctuations could impact international revenue and profitability performance.
  • Generic drug pricing pressure may affect North America business earnings visibility.

Summary

Cipla (NSE:CIPLA) reported FY26 revenue of Rs 28,163 crore, while EBITDA and PAT declined compared to FY25. The company recorded growth across India, North America and Africa businesses, with North America crossing US$ 400 million revenue benchmark. Cipla shares gained over 5% following the earnings announcement. The company maintained a net cash position exceeding US$ 1 billion during FY26.

FAQs

Q: What was Cipla’s revenue in FY26?
A: Cipla reported consolidated revenue of Rs 28,163 crore during FY26 financial year.

Q: Why did Cipla shares rise after Q4 FY26 results?
A: Shares gained after business growth updates and North America crossing US$ 400 million revenue benchmark.

Q: What was Cipla’s Q4 FY26 PAT figure?
A: Cipla reported profit after tax of Rs 555 crore during Q4 FY26 period.